📊 DXCM Key Takeaways
Is Dexcom Inc. (DXCM) a Good Investment?
DEXCOM demonstrates exceptional operational execution with robust free cash flow generation ($449M on $1.2B revenue), industry-leading margins (62.9% gross, 21.4% operating), and a fortress balance sheet with minimal debt. The company's 15.6% revenue growth combined with 47.2% EPS growth shows strong operational leverage and pricing power in a high-margin business.
DexCom shows a high-quality fundamental profile with double-digit revenue growth, much faster earnings growth, and strong free cash flow generation. Profitability is robust across gross, operating, and net margins, while the balance sheet remains very clean with ample liquidity and negligible long-term debt. The combination of growth, operating leverage, and financial strength supports a very favorable fundamental assessment.
Why Buy Dexcom Inc. Stock? DXCM Key Strengths
- Exceptional free cash flow generation with 37.7% FCF margin, converting profitability into cash at elite levels
- Industry-leading profitability across all levels: 62.9% gross margin, 21.4% operating margin, 16.7% net margin
- Fortress balance sheet with only $2.9M long-term debt, $1.1B cash, 1.95x current ratio, and virtually zero leverage (0.00x debt/equity)
- Revenue growth remains strong at 15.6% YoY, indicating continued demand expansion
- Profitability is improving meaningfully, with net income up 45.1% YoY and operating margin at 19.6%
- Financial health is excellent, supported by $917.7M in cash, strong liquidity ratios, minimal debt, and $1.08B in free cash flow
DXCM Stock Risks: Dexcom Inc. Investment Risks
- Modest return on equity (6.7%) and return on assets (3.0%) indicate potential capital deployment inefficiencies or asset over-capitalization
- Competitive pressures in continuous glucose monitoring market from larger diversified medical device companies
- Regulatory and reimbursement risks inherent in medical device sector; dependence on healthcare policy and insurance coverage decisions
- Growth quality depends on sustaining current adoption rates as the revenue base gets larger
- Margin expansion could slow if competition, reimbursement pressure, or product mix shifts weigh on gross margin
- Strong current returns may moderate if operating expenses or capital intensity rise faster than revenue
Key Metrics to Watch
- Free cash flow sustainability and growth trajectory
- Gross margin stability amid competitive dynamics
- Return on equity and asset efficiency improvement
- Operating margin consistency at 21%+ levels
- Revenue growth deceleration risks in core CGM market
- Gross and operating margin trends
- Revenue growth versus free cash flow conversion
Dexcom Inc. (DXCM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 37.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
DXCM Profit Margin, ROE & Profitability Analysis
DXCM vs Healthcare Sector: How Dexcom Inc. Compares
How Dexcom Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dexcom Inc. Stock Overvalued? DXCM Valuation Analysis 2026
Based on fundamental analysis, Dexcom Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dexcom Inc. Balance Sheet: DXCM Debt, Cash & Liquidity
DXCM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dexcom Inc.'s revenue has grown significantly by 90% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.30 reflects profitable operations.
DXCM Revenue Growth, EPS Growth & YoY Performance
DXCM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.0B | $105.4M | $0.27 |
| Q3 2025 | $994.2M | $134.6M | $0.34 |
| Q2 2025 | $1.0B | $143.5M | $0.35 |
| Q1 2025 | $921.0M | $105.4M | $0.27 |
| Q3 2024 | $975.0M | $120.7M | $0.29 |
| Q2 2024 | $871.3M | $115.9M | $0.28 |
| Q1 2024 | $741.5M | $48.6M | $0.12 |
| Q3 2023 | $769.6M | $101.2M | $0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Dexcom Inc. Dividends, Buybacks & Capital Allocation
DXCM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dexcom Inc. (CIK: 0001093557)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DXCM
What is the AI rating for DXCM?
Dexcom Inc. (DXCM) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (STRONG BUY) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DXCM's key strengths?
Claude: Exceptional free cash flow generation with 37.7% FCF margin, converting profitability into cash at elite levels. Industry-leading profitability across all levels: 62.9% gross margin, 21.4% operating margin, 16.7% net margin. ChatGPT: Revenue growth remains strong at 15.6% YoY, indicating continued demand expansion. Profitability is improving meaningfully, with net income up 45.1% YoY and operating margin at 19.6%.
What are the risks of investing in DXCM?
Claude: Modest return on equity (6.7%) and return on assets (3.0%) indicate potential capital deployment inefficiencies or asset over-capitalization. Competitive pressures in continuous glucose monitoring market from larger diversified medical device companies. ChatGPT: Growth quality depends on sustaining current adoption rates as the revenue base gets larger. Margin expansion could slow if competition, reimbursement pressure, or product mix shifts weigh on gross margin.
What is DXCM's revenue and growth?
Dexcom Inc. reported revenue of $1.2B.
Does DXCM pay dividends?
Dexcom Inc. does not currently pay dividends.
Where can I find DXCM SEC filings?
Official SEC filings for Dexcom Inc. (CIK: 0001093557) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DXCM's EPS?
Dexcom Inc. has a diluted EPS of $0.51.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DXCM a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Dexcom Inc. has a BUY rating with 86% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is DXCM stock overvalued or undervalued?
Valuation metrics for DXCM: ROE of 6.7% (sector avg: 15%), net margin of 16.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DXCM stock in 2026?
Our dual AI analysis gives Dexcom Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is DXCM's free cash flow?
Dexcom Inc.'s operating cash flow is $525.6M, with capital expenditures of $76.6M. FCF margin is 37.7%.
How does DXCM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 16.7% (avg: 12%), ROE 6.7% (avg: 15%), current ratio 1.95 (avg: 2).